News | May 30, 2024
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The collaboration aims to bolster healthcare entrepreneurship
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Subscribe To Our Newsletter & Stay Updated
